$87.85
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. The company is headquartered in Orlando, Florida and currently employs 166 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
Country

US

CEO

Mr. Roger Susi

IPO date

2014

Employees

166

ISIN

US46266A1097

Key stats

Open

$86.83

Volume

76.20K

Market cap

$1.12B

Prev. close

$87.85

Impl / hst vl

-

Open interest

$0.00

$86.33

Day’s Range

$87.95

$76.95

52W Range

$107.90

Valuation

44
Valuation score
Fairly Valued
P/E
48.23
P/S
12.88
P/B
10.93
Current ratio
9.46
Debt / Equity
-0.58
ROE
23.45%
Gross margin
74.07%
Income growth
-10.31%
FCF growth
-29.71

Aug

28

Dividends

The last payment date was Aug 28, 2026

Div. per Share

$0.20

Div. Yield

0.23%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$120.36
The top 4 analysts forecasts that 12-month price may increase by 37.01%, with a low of $117.16 and a high of $126.00
$117.16
Low
$120.36
Avg
$126.00
High
Current price

Earnings

Q2 ‘26 revenue
$20.47M
Q2 ‘26 net income
$5.22M
Revenue
Net income
Previous EPS
$0.49
Estimate EPS
$0.43
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply